WO2002040006A3 - Treatment of anxiety disorders - Google Patents

Treatment of anxiety disorders Download PDF

Info

Publication number
WO2002040006A3
WO2002040006A3 PCT/US2001/027801 US0127801W WO0240006A3 WO 2002040006 A3 WO2002040006 A3 WO 2002040006A3 US 0127801 W US0127801 W US 0127801W WO 0240006 A3 WO0240006 A3 WO 0240006A3
Authority
WO
WIPO (PCT)
Prior art keywords
anxiety disorders
treatment
tomoxetine
reboxetine
reuptake inhibitors
Prior art date
Application number
PCT/US2001/027801
Other languages
French (fr)
Other versions
WO2002040006A2 (en
Inventor
Holly Ann Read
David Michelson
Original Assignee
Lilly Co Eli
Holly Ann Read
David Michelson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP01996376A priority Critical patent/EP1395253A2/en
Priority to SK542-2003A priority patent/SK5422003A3/en
Priority to AU2002217757A priority patent/AU2002217757A1/en
Priority to IL15587401A priority patent/IL155874A0/en
Priority to US10/416,294 priority patent/US20040034106A1/en
Priority to MXPA03004190A priority patent/MXPA03004190A/en
Priority to CA002426069A priority patent/CA2426069A1/en
Priority to BR0115301-3A priority patent/BR0115301A/en
Application filed by Lilly Co Eli, Holly Ann Read, David Michelson filed Critical Lilly Co Eli
Priority to EA200300567A priority patent/EA200300567A1/en
Priority to JP2002542380A priority patent/JP2004529073A/en
Priority to CNA01818927XA priority patent/CN1822825A/en
Priority to HU0301863A priority patent/HUP0301863A2/en
Priority to KR10-2003-7006523A priority patent/KR20030051812A/en
Publication of WO2002040006A2 publication Critical patent/WO2002040006A2/en
Priority to NO20032156A priority patent/NO20032156D0/en
Priority to HR20030384A priority patent/HRP20030384A2/en
Publication of WO2002040006A3 publication Critical patent/WO2002040006A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Selective norepinephrine reuptake inhibitors including tomoxetine and reboxetine are used to treat anxiety disorders, especially obsessive-compulsive disorder.
PCT/US2001/027801 2000-11-15 2001-11-06 Treatment of anxiety disorders WO2002040006A2 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
EA200300567A EA200300567A1 (en) 2000-11-15 2001-11-06 TREATMENT OF THE ALARM CONDITIONS
SK542-2003A SK5422003A3 (en) 2000-11-15 2001-11-06 Treatment of anxiety disorders
JP2002542380A JP2004529073A (en) 2000-11-15 2001-11-06 Anxiety disorder treatment
US10/416,294 US20040034106A1 (en) 2001-11-06 2001-11-06 Treatment of anxiety disorders
MXPA03004190A MXPA03004190A (en) 2000-11-15 2001-11-06 Treatment of anxiety disorders.
CA002426069A CA2426069A1 (en) 2000-11-15 2001-11-06 Treatment of anxiety disorders
BR0115301-3A BR0115301A (en) 2000-11-15 2001-11-06 Use of a selective norepinephrine reuptake inhibitor
EP01996376A EP1395253A2 (en) 2000-11-15 2001-11-06 Treatment of anxiety disorders
AU2002217757A AU2002217757A1 (en) 2000-11-15 2001-11-06 Treatment of anxiety disorders
IL15587401A IL155874A0 (en) 2000-11-15 2001-11-06 Treatment of anxiety disorders
CNA01818927XA CN1822825A (en) 2000-11-15 2001-11-06 Treatment of anxiety disorders
HU0301863A HUP0301863A2 (en) 2000-11-15 2001-11-06 Treatment of anxiety disorders by selective norepinephrine reuptake inhibitors
KR10-2003-7006523A KR20030051812A (en) 2000-11-15 2001-11-06 Treatment of Anxiety Disorders
NO20032156A NO20032156D0 (en) 2000-11-15 2003-05-13 Treatment of anxiety disorders
HR20030384A HRP20030384A2 (en) 2000-11-15 2003-05-14 Treatment of anxiety disorders

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24901000P 2000-11-15 2000-11-15
US60/249,010 2000-11-15
US26536201P 2001-01-31 2001-01-31
US60/265,362 2001-01-31

Publications (2)

Publication Number Publication Date
WO2002040006A2 WO2002040006A2 (en) 2002-05-23
WO2002040006A3 true WO2002040006A3 (en) 2003-12-24

Family

ID=26939750

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/027801 WO2002040006A2 (en) 2000-11-15 2001-11-06 Treatment of anxiety disorders

Country Status (16)

Country Link
EP (1) EP1395253A2 (en)
JP (1) JP2004529073A (en)
KR (1) KR20030051812A (en)
CN (1) CN1822825A (en)
AU (1) AU2002217757A1 (en)
BR (1) BR0115301A (en)
CA (1) CA2426069A1 (en)
CZ (1) CZ20031339A3 (en)
EA (1) EA200300567A1 (en)
HR (1) HRP20030384A2 (en)
IL (1) IL155874A0 (en)
MX (1) MXPA03004190A (en)
NO (1) NO20032156D0 (en)
PL (1) PL366119A1 (en)
SK (1) SK5422003A3 (en)
WO (1) WO2002040006A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL363840A1 (en) * 2001-03-06 2004-11-29 Eli Lilly And Company Inhibitor of monoamine uptake
EP1530476A1 (en) * 2002-08-14 2005-05-18 Pharmacia & Upjohn Company LLC Use of reboxetine for the treatment of hot flashes
GB0309440D0 (en) * 2003-04-25 2003-06-04 Lilly Co Eli Quinolone derivatives
WO2004103356A2 (en) * 2003-05-15 2004-12-02 Eli Lilly And Company Treatment of emotional dysregulation
DE602004014823D1 (en) * 2003-12-12 2008-08-14 Lilly Co Eli SELECTIVE NOREPINEPHRINE RECOVERY INHIBITOR FOR THE TREATMENT OF HITZEWALLUNGEN
EP2234960A2 (en) 2008-01-09 2010-10-06 Mayo Foundation for Medical Education and Research Inhibiting neurotransmitter reuptake
WO2011056788A2 (en) * 2009-11-03 2011-05-12 Mayo Foundation For Medical Education And Research Inhibiting neurotransmitter reuptake
WO2011056773A2 (en) * 2009-11-03 2011-05-12 Mayo Foundation For Medical Education And Research Inhibiting neurotransmitter reuptake
WO2014159251A2 (en) 2013-03-14 2014-10-02 Mayo Foundation For Medical Education And Research Inhibiting neurotransmitter reuptake
EA202192084A1 (en) * 2019-02-01 2021-10-20 ХОФФМАН ТЕКНОЛОДЖИЗ ЭлЭлСи. COMPOSITIONS AND METHODS FOR TREATMENT OF ANXIETY DISORDERS

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997041878A1 (en) * 1996-05-07 1997-11-13 Merck & Co., Inc. Treatment of mood disorders with a growth hormone secretagogue
WO1999052518A2 (en) * 1998-04-13 1999-10-21 Pharmacia & Upjohn S.P.A. New treatments for nervous disorders
WO2001001973A2 (en) * 1999-07-01 2001-01-11 Pharmacia & Upjohn Company Highly selective norepinephrine reuptake inhibitors and methods of using the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997041878A1 (en) * 1996-05-07 1997-11-13 Merck & Co., Inc. Treatment of mood disorders with a growth hormone secretagogue
WO1999052518A2 (en) * 1998-04-13 1999-10-21 Pharmacia & Upjohn S.P.A. New treatments for nervous disorders
WO2001001973A2 (en) * 1999-07-01 2001-01-11 Pharmacia & Upjohn Company Highly selective norepinephrine reuptake inhibitors and methods of using the same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"TOMOXETINE HYDROCHLORIDE", DRUGS OF THE FUTURE, BARCELONA, ES, vol. 11, 1986, pages 134 - 135, XP008015974, ISSN: 0377-8282 *
CHOUINARD G ET AL: "FREE COMMUNICATIONS-SESSION A AN EARLY PHASE II CLINICAL TRIAL WITH FOLLOWUP OF TOMOXETINE ( Y139603) IN THE TREATMENT OF NEWLY ADMITTED DEPRESSED PATIENTS", PSYCHOPHARMACOLOGY BULLETIN, BETHESDA, MD, US, vol. 21, no. 1, 1985, pages 73 - 76, XP000603882, ISSN: 0048-5764 *
MANFRED P SCHNEIDER ET AL: "An efficient route to enantiomerically pure antidepressants: Tomoxetine, Nisoxetine and Fluoxetine", TETRAHEDRON: ASYMMETRY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 3, no. 4, April 1992 (1992-04-01), pages 525 - 528, XP002109756, ISSN: 0957-4166 *

Also Published As

Publication number Publication date
CN1822825A (en) 2006-08-23
NO20032156L (en) 2003-05-13
PL366119A1 (en) 2005-01-24
SK5422003A3 (en) 2003-12-02
IL155874A0 (en) 2003-12-23
AU2002217757A1 (en) 2002-05-27
EA200300567A1 (en) 2004-10-28
NO20032156D0 (en) 2003-05-13
MXPA03004190A (en) 2003-09-22
WO2002040006A2 (en) 2002-05-23
HRP20030384A2 (en) 2003-08-31
CA2426069A1 (en) 2002-05-23
BR0115301A (en) 2004-12-14
KR20030051812A (en) 2003-06-25
CZ20031339A3 (en) 2003-10-15
JP2004529073A (en) 2004-09-24
EP1395253A2 (en) 2004-03-10

Similar Documents

Publication Publication Date Title
WO2002053140A3 (en) New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
HUP0201623A3 (en) Use of (s,s)reboxetine a selective norepinephrine reuptake inhibitor for the preparation of pharmaceutical compositions treating disorders of the nervous system
WO2004047830A3 (en) Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor and the use of said composition for treating bladder dysfunction
WO2001078702A3 (en) Methods and compositions for modulating alpha adrenergic receptor activity
WO2001062341A3 (en) Combination product for the treatment of obesity
WO2004066990A3 (en) Methods of treating lower urinary tract disorders using sodium channel modulators
ZA200300411B (en) Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders.
WO2004009776A3 (en) TREATMENT OF TNFα RELATED DISORDERS
TR200000755T2 (en) Treatment of anti-oppositional disorder.
WO2001078703A3 (en) Methods and compositions for modulating alpha adrenergic receptor activity
HUP0401808A3 (en) Dosage forms, devices and methods of treatment
WO2002040006A3 (en) Treatment of anxiety disorders
HK1041880A1 (en) Compounds and methods for treatment of asthma, allergy and inflammatory disorders.
WO2004103283A3 (en) Compositions of a cyclooxygenase-2 selective inhibitor and a central nervous system stimulant for the treatment of central nervous system damage
EE05357B1 (en) A tablet containing at least two distinct segments and its use
WO2000002551A3 (en) Methods and compounds for treating depression
WO2003033557A3 (en) Copolymers containing fluorine, method for the production and use thereof
MY136367A (en) Treatment of cognitive failure
MXPA03007653A (en) Use of lp82 to treat hematopoietic disorders.
YU89103A (en) Novel treatment for obsessive-compulsive disorder (ocd) and ocd-related disorders using gvg
NO20061425L (en) The combination of a serotonin reuptake inhibitor and loxapine
ZA200403409B (en) Methods for treating depression and other CNS disorders using enantiomerically enriched desmethyl- and didesmethyl-metabolites of citalopram.
ZA200205098B (en) Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of cox-2-mediated disorders.
AU2001247471A1 (en) Compositions and methods of treating, reducing, and preventing cardiovascular diseases and disorders with polymethoxyflavones
AU2002347984A1 (en) Use of norepinephrine reuptake inhibitors for the treatment of tic disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2426069

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 5422003

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 2002217757

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 10416294

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 155874

Country of ref document: IL

Ref document number: 601/KOLNP/2003

Country of ref document: IN

Ref document number: 1200300423

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/004190

Country of ref document: MX

Ref document number: 1-2003-500348

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: PV2003-1339

Country of ref document: CZ

Ref document number: 2003/03738

Country of ref document: ZA

Ref document number: P20030384A

Country of ref document: HR

Ref document number: 1020037006523

Country of ref document: KR

Ref document number: 525853

Country of ref document: NZ

Ref document number: 200303738

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2001996376

Country of ref document: EP

Ref document number: 2002542380

Country of ref document: JP

Ref document number: 01818927X

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 200300567

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 1020037006523

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2003-1339

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 2001996376

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001996376

Country of ref document: EP